Tearsheet
Investment Highlights Market Valuation Price Chart Business Description Interactive Breakdown Latest Trefis Analyses Better Bets vs. SYK Recent Active Movers More From Trefis Peer Financials Peer Growth & Margins Peer Valuation Peer Returns Peer Analyses FDIC Bank Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Insider Activity Industry Resource Links External Quote Links

Stryker (SYK)

Market Price (9/18/2025): $376.88 | Market Cap: $144.0 Bil
Sector: Health Care | Industry: Health Care Equipment

Stryker (SYK)

Market Price (9/18/2025): $376.88
Market Cap: $144.0 Bil
Sector: Health Care
Industry: Health Care Equipment

Investment Highlights

0 Attractive operating margins
Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 20%		 Weak multi-year price returns
2Y Excs Rtn is -19%		 Expensive valuation multiples
P/EBITPrice/EBIT or Price/(Operating Income) ratio is 31x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 30x, P/EPrice/Earnings or Price/(Net Income) is 49x
1 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 20%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 17%, CFO LTM is 4.8 Bil, FCF LTM is 4.0 Bil		  
2 Low stock price volatility
Vol 12M is 22%		  
0 Attractive operating margins
Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 20%
1 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 20%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 17%, CFO LTM is 4.8 Bil, FCF LTM is 4.0 Bil
2 Low stock price volatility
Vol 12M is 22%
3 Weak multi-year price returns
2Y Excs Rtn is -19%
4 Expensive valuation multiples
P/EBITPrice/EBIT or Price/(Operating Income) ratio is 31x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 30x, P/EPrice/Earnings or Price/(Net Income) is 49x

Market Valuation

 9/18/252024202320222021
Share Price CYE$376.88$358.45$295.41$238.62$257.74
Market Cap CYE ($ Bil)144.0136.7112.290.397.3
Total Debt ($ Bil)16.613.613.013.012.5
Total Cash ($ Bil)2.54.53.11.93.0
Enterprise Value ($ Bil)158.2150.3125.2103.3109.8
Valuation Ratios     
P/S TTM6.06.15.55.05.9
P/EBIT TTM30.829.429.029.737.5
P/E TTM49.445.835.939.250.6
Sector Ratios     
P/S TTM (Sector)3.83.64.14.57.3
P/EBIT TTM (Sector)-1.6-1.3-1.4-1.3-2.9
P/E TTM (Sector)-1.8-1.5-1.5-1.3-2.9
 9/18/2520242023
Share Price CYE$376.88$358.45$295.41
Market Cap CYE ($ Bil)144.0136.7112.2
Total Debt ($ Bil)16.613.613.0
Total Cash ($ Bil)2.54.53.1
Enterprise Value ($ Bil)158.2150.3125.2
Valuation Ratios   
P/S TTM6.06.15.5
P/EBIT TTM30.829.429.0
P/E TTM49.445.835.9
Sector Ratios   
P/S TTM (Sector)3.83.64.1
P/EBIT TTM (Sector)-1.6-1.3-1.4
P/E TTM (Sector)-1.8-1.5-1.5

Market Cap Chart

Business Description

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. Show more

Price Returns Compared

Expand for Detailed View

 202020212022202320242025Total [1]
Returns
SYK Return18%10%-7%24%21%5%94%
Peers Return10%4%-11%9%4%8%25%
S&P 500 Return16%27%-19%24%23%12%104%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: JNJ, MDT, ZBH, ITGR, ABT. See SYK Returns vs. Peers.
[3] 2025 data is for the year up to 9/17/2025 (YTD)

Better Bets than Stryker (SYK)

 SYKBetter Performance than SYK
MetricValueIndustry (Health Care Equipment)
Rev Chg LTM11.4%ISRG (20.8%), BSX (21.4%), PODD (26.0%), PEN (12.9%), GMED (17.4%)
Rev Chg 3Y Avg10.6%ISRG (15.4%), BSX (14.6%), RMD (12.9%), DXCM (17.3%), PODD (26.1%)
Op Mgn LTM19.7%ISRG (28.8%), IDXX (31.1%), EW (27.9%), RMD (32.8%), LMAT (23.3%)
CFO/Rev LTM20.0%ABT (21.0%), ISRG (30.9%), BSX (23.2%), MDT (20.9%), IDXX (22.4%)
FCF/Rev LTM16.9%ISRG (21.8%), BSX (17.5%), IDXX (19.2%), RMD (32.1%), ZBH (17.7%)
Total Yield2.9%ABT (7.7%), MDT (6.8%), BDX (5.1%), EW (9.4%), RMD (4.3%)
 SYKBetter Performance than SYK
MetricValueAll Other Sectors
Rev Chg LTM11.4%NVDA (71.6%), MSFT (14.9%), GOOGL (13.1%), META (19.4%), AVGO (28.0%)
Rev Chg 3Y Avg10.6%NVDA (92.0%), MSFT (12.5%), AMZN (11.3%), META (13.0%), AVGO (24.0%)
Op Mgn LTM19.7%NVDA (58.1%), MSFT (45.6%), AAPL (31.9%), GOOGL (32.7%), META (42.9%)
CFO/Rev LTM20.0%NVDA (46.6%), MSFT (48.3%), AAPL (26.6%), GOOGL (36.0%), META (56.4%)
FCF/Rev LTM16.9%NVDA (43.6%), MSFT (25.4%), AAPL (23.5%), GOOGL (18.0%), META (30.7%)
Total Yield2.9%MSFT (3.3%), AAPL (3.2%), GOOGL (4.1%), META (3.7%), BRK-B (5.9%)

Latest Trefis Analyses

TitleTopicDate
0DASHBOARDS  
1Stryker Earnings Notes  
2Stryker vs Microsoft: Which Is A Better Investment?Counter-Intuitive Comparisons 
3Stryker vs Eli Lilly: Which Is A Better Investment?Counter-Intuitive Comparisons 
4SYK Testing Price Floor: Time to Load Up?Actionable 
5Wait For A Dip To Buy Stryker StockBuy or Fear 
6How Does SYK Stack Up Against Its Peers?Peer Comparison 
7Better Bet Than SYK Stock: Pay Less Than Stryker To Get More From META, LLY   
8Better Bet Than SYK Stock: Pay Less Than Stryker To Get More From LLY, MCK   
9Better Bet Than SYK Stock: Pay Less Than Stryker To Get More From GMED   
10Better Bet Than SYK Stock: Pay Less Than Stryker To Get More From GMED, UFPT Actionable 
11ARTICLES  
12SYK Hits Key Support – Is This The Buying Opportunity? August 15th, 2025
13Wait for a dip to buy Stryker stock August 14th, 2025
14Better Bet Than Stryker Stock: Pay Less To Get More From GMED, UFPT August 2nd, 2025
15S&P 500 Stocks Trading At 52-Week High July 24th, 2025
16Better Bet Than Stryker Stock: Pay Less To Get More From GMED, UFPT July 23rd, 2025
Title
0DASHBOARDS
1SYK Hits Key Support – Is This The Buying Opportunity?
2Wait for a dip to buy Stryker stock
3Better Bet Than Stryker Stock: Pay Less To Get More From GMED, UFPT
4S&P 500 Stocks Trading At 52-Week High
5Better Bet Than Stryker Stock: Pay Less To Get More From GMED, UFPT
6ARTICLES
7Stryker Earnings Notes
8Stryker vs Microsoft: Which Is A Better Investment?
9Stryker vs Eli Lilly: Which Is A Better Investment?
10SYK Testing Price Floor: Time to Load Up?
11Wait For A Dip To Buy Stryker Stock
12How Does SYK Stack Up Against Its Peers?
13Better Bet Than SYK Stock: Pay Less Than Stryker To Get More From META, LLY 
14Better Bet Than SYK Stock: Pay Less Than Stryker To Get More From LLY, MCK 
15Better Bet Than SYK Stock: Pay Less Than Stryker To Get More From GMED 
16Better Bet Than SYK Stock: Pay Less Than Stryker To Get More From GMED, UFPT 

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1ECDAECD Automotive Design3347.2%307.9%
2BDSXBiodesix1090.6%-79.7%
3CLSDClearside Biomedical987.7%-74.7%
4ATHAAthira Pharma892.1%544.3%
5SDOTSadot690.6%-79.9%
6ATCHAtlasClear684.9%-83.1%
7HSDTHelius Medical Technologies232.1%-95.5%
8CHEKCheck-Cap222.2%134.4%
9APLMApollomics197.8%89.1%
10SPRCSciSparc147.0%1141.7%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1CURXCuranex Pharmaceuticals-80.5%148.4%
2ATYRaTyr Pharma-80.4%-71.7%
3NAKAKindly MD-70.2% 
4BNGOBionano Genomics-64.0%-89.8%
5XAGELongevity Health-57.6%-86.1%
6FAASDigiAsia-55.4%-88.0%
7ASSTStrive-54.5%650.3%
8VCIGVCI Global-51.0%-98.9%
9REXREX American Resources-50.7%44.3%
10RBNERobin Energy-42.6% 

1 Month Top Gainers

#TickerCompany1M RtnYTD Rtn
1PMIPicard Medical11931.7%11931.7%
2GIBOGIBO10714.0% 
3LNZALanzaTech Global8455.2%-86.3%
4GTIGraphjet Technology3998.4%-93.1%
5GWAVGreenwave Technology Solutions3582.8%-91.4%
6QMMMQMMM3409.6%8153.1%
7ECDAECD Automotive Design2715.2%307.9%
8OESXOrion Energy Systems1373.7%14.2%
9OPOceanPal1266.5%-95.6%
10BCTXBriaCell Therapeutics1032.4%-89.8%

1 Month Top Losers

#TickerCompany1M RtnYTD Rtn
1CJETChijet Motor-94.5%-96.0%
2STFSStar Fashion Culture-92.3%-97.9%
3ELPWElong Power-91.1%-76.9%
4NXTTNext Technology-90.1%-95.4%
5EPIXESSA Pharma-89.4%-8.9%
6NAKAKindly MD-88.1% 
7BINIBollinger Innovations-87.6%-100.0%
8JEM707 Cayman-87.4%-98.2%
9YAASYouxin Technology-83.3%-98.4%
10NEONNeonode-82.5%-51.0%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1ECDAECD Automotive Design3347.2%307.9%
2BDSXBiodesix1090.6%-79.7%
3CLSDClearside Biomedical987.7%-74.7%
4ATHAAthira Pharma892.1%544.3%
5SDOTSadot690.6%-79.9%
6ATCHAtlasClear684.9%-83.1%
7HSDTHelius Medical Technologies232.1%-95.5%
8CHEKCheck-Cap222.2%134.4%
9APLMApollomics197.8%89.1%
10SPRCSciSparc147.0%1141.7%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1CURXCuranex Pharmaceuticals-80.5%148.4%
2ATYRaTyr Pharma-80.4%-71.7%
3NAKAKindly MD-70.2% 
4BNGOBionano Genomics-64.0%-89.8%
5XAGELongevity Health-57.6%-86.1%
6FAASDigiAsia-55.4%-88.0%
7ASSTStrive-54.5%650.3%
8VCIGVCI Global-51.0%-98.9%
9REXREX American Resources-50.7%44.3%
10RBNERobin Energy-42.6% 

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Stryker

Financials

SYKJNJMDTZBHITGRABTMedian
NameStryker Johnson .MedtronicZimmer B.Integer Abbott L. 
Mkt Price376.88177.2094.5899.92102.69134.17118.43
Mkt Cap144.0426.4121.219.83.6233.9132.6
Rev LTM23,81890,62734,2007,8341,79543,10929,009
Op Inc LTM4,68322,2286,6471,4752367,5155,665
FCF LTM4,02416,3975,3031,3841206,7754,664
FCF 3Y Avg3,08116,9264,9641,173735,9724,023
CFO LTM4,76623,0287,1461,6632109,0375,956
CFO 3Y Avg3,73522,2486,6251,5121808,1305,180

Growth & Margins

SYKJNJMDTZBHITGRABTMedian
NameStryker Johnson .MedtronicZimmer B.Integer Abbott L. 
Rev Chg LTM11.4%4.7%5.0%4.1%9.6%5.9%5.4%
Rev Chg 3Y Avg10.6%4.0%3.3%4.3%12.0%-1.5%4.1%
Rev Chg Q11.1%5.8%8.4%7.0%11.4%7.4%7.9%
QoQ Delta Rev Chg LTM2.6%1.5%2.0%1.8%2.8%1.8%1.9%
Op Mgn LTM19.7%24.5%19.4%18.8%13.1%17.4%19.1%
Op Mgn 3Y Avg19.3%26.3%18.6%19.2%11.8%16.2%18.9%
QoQ Delta Op Mgn LTM-0.1%-0.2%-0.1%-0.4%0.0%0.6%-0.1%
CFO/Rev LTM20.0%25.4%20.9%21.2%11.7%21.0%20.9%
CFO/Rev 3Y Avg17.2%25.7%20.2%20.1%11.0%19.6%19.9%
FCF/Rev LTM16.9%18.1%15.5%17.7%6.7%15.7%16.3%
FCF/Rev 3Y Avg14.1%19.6%15.1%15.5%4.3%14.4%14.8%

Valuation

SYKJNJMDTZBHITGRABTMedian
NameStryker Johnson .MedtronicZimmer B.Integer Abbott L. 
Mkt Cap144.0426.4121.219.83.6233.9132.6
P/S6.04.73.52.52.05.44.1
P/EBIT30.815.118.916.022.227.820.6
P/E49.418.826.024.043.516.725.0
P/CFO30.218.517.011.917.125.917.8
Total Yield2.9%8.1%6.8%5.1%2.3%7.7%6.0%
Dividend Yield0.9%2.8%3.0%1.0%0.0%1.7%1.3%
FCF Yield 3Y Avg2.3%4.5%4.5%5.3%1.9%3.0%3.7%
D/E0.10.10.20.40.40.10.2
Net D/E0.10.10.20.40.40.00.1

Returns

SYKJNJMDTZBHITGRABTMedian
NameStryker Johnson .MedtronicZimmer B.Integer Abbott L. 
1M Rtn-1.2%1.3%1.9%-2.6%-2.7%3.0%0.0%
3M Rtn1.2%18.4%11.2%10.3%-13.7%1.8%6.1%
6M Rtn0.1%10.5%4.6%-11.3%-14.9%6.3%2.4%
12M Rtn4.5%9.5%10.3%-5.3%-18.6%15.8%7.0%
3Y Rtn75.7%15.8%15.8%-9.3%63.4%36.8%26.3%
1M Excs Rtn-3.6%-1.1%-0.4%-4.9%-5.0%0.6%-2.3%
3M Excs Rtn-9.2%6.8%0.3%0.4%-24.1%-8.4%-4.0%
6M Excs Rtn-16.9%-7.9%-13.3%-28.8%-31.3%-10.4%-15.1%
12M Excs Rtn-14.6%-6.8%-8.7%-22.7%-36.3%0.2%-11.7%
3Y Excs Rtn7.1%-43.4%-47.1%-74.9%-4.0%-30.4%-36.9%

Comparison Analyses

Financials

$ Mil | FY: 12/312025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q32023Q22023Q12022Q42022Q3
Period End6/30/20253/31/202512/31/20249/30/20246/30/20243/31/202412/31/20239/30/20236/30/20233/31/202312/31/20229/30/2022
Filing Date8/1/20255/2/20252/12/202510/30/20247/31/20245/1/20242/14/202411/3/20238/4/20235/2/20232/10/202311/1/2022
Key Financials Quarterly            
Total Revenue6,0225,8666,4365,4945,4225,2435,8154,9094,9964,7785,2024,479
Ebitda1,4641,1441,8221,3531,3251,2351,5431,1931,2249921,3231,054
Operating Income1,1688721,5581,0851,0679751,2939319657351,070804
Net Income8846545468348257881,143692738592563816
EPS2.321.711.432.182.172.073.011.821.951.561.482.16
Key Financials TTM            
Total Revenue TTM23,81823,21822,59521,97421,38920,96320,49819,88519,45518,95218,44917,948
Ebitda TTM5,7835,6445,7355,4565,2965,1954,9524,7324,5934,3984,1093,848
Operating Income TTM4,6834,5824,6854,4204,2664,1643,9243,7013,5743,3853,1112,865
Net Income TTM2,9182,8592,9933,5903,4483,3613,1652,5852,7092,6272,3582,457
Growth Rates Quarterly            
Total Revenue Growth11.1%11.9%10.7%11.9%8.5%9.7%11.8%9.6%11.2%11.8%10.7%7.7%
EBITDA Growth10.5%-7.4%18.1%13.4%8.3%24.5%16.6%13.2%19.0%41.1%24.6%27.8%
Operating Income Growth9.5%-10.6%20.5%16.5%10.6%32.7%20.8%15.8%24.4%59.4%29.9%36.3%
Net Income Growth7.2%-17.0%-52.2%20.5%11.8%33.1%103.0%-15.2%12.5%83.3%-15.0%86.3%
Margins Quarterly            
EBITDA Margin24.3%19.5%28.3%24.6%24.4%23.6%26.5%24.3%24.5%20.8%25.4%23.5%
Operating Income Margin19.4%14.9%24.2%19.7%19.7%18.6%22.2%19.0%19.3%15.4%20.6%18.0%
Net Income Margin14.7%11.1%8.5%15.2%15.2%15.0%19.7%14.1%14.8%12.4%10.8%18.2%
Cash & Debt            
Total Cash2,4642,4094,4934,6841,9572,4073,0531,9361,4781,7571,9281,497
Total Debt16,58016,78113,59715,48412,22212,86512,99512,69012,94713,06113,04812,759
Net Debt / (Cash)14,11614,3729,10410,80010,26510,4589,94210,75411,46911,30411,12011,262
Cash Flows Quarterly            
FCF from Operations1,1112501,9311,4746332041,5281,0506884451,003889
Cash Flows TTM            
FCF from Operations TTM4,7664,2884,2423,8393,4153,4703,7113,1863,0252,8662,6242,621
Returns to Shareholders Quarterly            
Dividends321320305305305304285285285284263263
Share Repurchases-0-0-0-0-0-0-0-0-0-0-0-0
Return on Invested Capital (ROIC) Quarterly            
ROIC25.6%18.2%55.6%27.4%28.8%26.9%41.0%23.3%23.8%19.5%24.4%24.3%
Return on Invested Capital (ROIC) TTM            
ROIC TTM25.7%23.9%35.8%29.9%29.9%28.9%28.7%23.4%23.1%22.8%21.1%19.8%

Segment Financials

Revenue by Segment

$ Mil20242023202220212020
MedSurg and Neurotechnology12,16310,8939,5388,345 
Orthopaedics8,3357,556  5,252
Orthopaedics and Spine  7,5706,006 
MedSurg    6,492
Neurotechnology & Spine    3,140
Total20,49818,44917,10814,35114,884


Operating Income by Segment
$ Mil20242023202220212020
MedSurg and Neurotechnology3,4702,8312,8072,414 
Orthopaedics2,2652,202  1,907
Inventory stepped up to fair value00   
Recall-related matters-1815-103-17-192
Acquisition and integration-related charges-20-138-585-242-275
Goodwill and other impairments-36-270   
Regulatory and legal matters-92-762-624
Medical device regulation-96-140-107-81-62
Structural optimization and other special charges-170-295-386-458-226
Amortization of intangible assets-635-627-619-472-464
Corporate and Other-780-649-605-503-480
Orthopaedics and Spine  2,1801,588 
MedSurg    1,642
Neurotechnology & Spine    839
Total3,8882,8532,5842,2232,713


Assets by Segment
$ Mil20242023202220212020
MedSurg and Neurotechnology20,804  15,250 
Orthopaedics18,023   9,085
Corporate and Other1,085  9901,370
Orthopaedics and Spine   18,090 
MedSurg    12,066
Neurotechnology & Spine    7,646
Total39,912  34,33030,167


Price Behavior

SYK Betas & Captures as of 8/31/2025

 1M2M3M6M1Y3Y
Beta0.890.970.840.760.720.78
Up Beta1.110.740.670.720.700.82
Down Beta2.361.871.510.800.740.81
Up Capture32%55%58%68%60%52%
Bmk +ve Days10223571142415
Stock +ve Days10193162122397
Down Capture54%114%91%86%80%90%
Bmk -ve Days11192754106334
Stock -ve Days11223163126353

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date8292025
Short Interest: Shares Quantity4,185,083
Short Interest: % Change Since 8152025-1.4%
Average Daily Volume1,066,321
Days-to-Cover Short Interest3.92
Basic Shares Quantity382,200,000
Short % of Basic Shares1.1%

Returns Analyses

Earnings Returns History

Expand for More

 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
7/31/2025-3.8%-4.2%-0.3%
5/1/20251.1%2.3%1.8%
1/28/2025-1.0%-0.7%-1.6%
10/29/20241.2%3.0%8.1%
7/30/2024-0.8%-2.3%7.9%
4/30/2024-2.5%-1.3%1.2%
1/30/20245.9%7.3%10.2%
11/2/2023-0.7%-2.7%4.6%
...
SUMMARY STATS   
# Positive81215
# Negative16129
Median Positive2.1%2.6%4.6%
Median Negative-1.8%-3.7%-6.2%
Max Positive9.9%7.3%13.6%
Max Negative-4.3%-10.0%-9.3%

SEC Filings

Expand for More

Report DateFiling DateFiling
6302025801202510-Q 6/30/2025
3312025502202510-Q 3/31/2025
12312024212202510-K 12/31/2024
93020241030202410-Q 9/30/2024
6302024731202410-Q 6/30/2024
3312024501202410-Q 3/31/2024
12312023214202410-K 12/31/2023
93020231103202310-Q 9/30/2023
6302023804202310-Q 6/30/2023
3312023502202310-Q 3/31/2023
12312022210202310-K 12/31/2022
93020221101202210-Q 9/30/2022
6302022727202210-Q 6/30/2022
3312022429202210-Q 3/31/2022
12312021211202210-K 12/31/2021
93020211029202110-Q 9/30/2021

Insider Activity

Expand for More

 OwnerTitleFiling DateActionPriceSharesTransacted
Value		Value of
Held Shares		Form
0Menon VijuGroup President8272025Sell390.61500195,3054,886,922Form
1Fletcher Robert SVP, Chief Legal Officer8212025Sell393.071,785701,6304,110,333Form
2STRYKER RONDA E 8072025Sell374.9934,91113,091,2761,270,165,003Form
3Berry William E JrVP, Chief Accounting Officer5142025Sell388.561,241482,2021,100,789Form
4STRYKER RONDA E 5082025Sell374.7618,3626,881,3301,347,883,283Form

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.